HK1198288A1 - Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivate - Google Patents

Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivate Download PDF

Info

Publication number
HK1198288A1
HK1198288A1 HK14111805.6A HK14111805A HK1198288A1 HK 1198288 A1 HK1198288 A1 HK 1198288A1 HK 14111805 A HK14111805 A HK 14111805A HK 1198288 A1 HK1198288 A1 HK 1198288A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical composition
weight
controlled release
release layer
group
Prior art date
Application number
HK14111805.6A
Other languages
English (en)
Chinese (zh)
Inventor
．法納拉
D．法纳拉
．艾克曼
F．艾克曼
．貝爾韋爾
M．贝尔韦尔
Original Assignee
Ucb医药有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb医药有限公司 filed Critical Ucb医药有限公司
Publication of HK1198288A1 publication Critical patent/HK1198288A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK14111805.6A 2008-11-18 2014-11-21 Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivate HK1198288A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP08105817 2008-11-18
EP08105817.4 2008-11-18
EP09100311 2009-06-02
EP09100311.1 2009-06-02

Publications (1)

Publication Number Publication Date
HK1198288A1 true HK1198288A1 (en) 2015-03-27

Family

ID=41395028

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14111805.6A HK1198288A1 (en) 2008-11-18 2014-11-21 Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivate

Country Status (18)

Country Link
US (1) US8460712B2 (enExample)
EP (1) EP2358361B1 (enExample)
JP (2) JP5954889B2 (enExample)
KR (2) KR101788804B1 (enExample)
CN (2) CN102215828A (enExample)
AU (1) AU2009317279B2 (enExample)
BR (1) BRPI0921301A2 (enExample)
CA (1) CA2741038C (enExample)
DK (1) DK2358361T3 (enExample)
EA (1) EA019583B1 (enExample)
ES (1) ES2602606T3 (enExample)
HK (1) HK1198288A1 (enExample)
HU (1) HUE030963T2 (enExample)
IL (1) IL212271A (enExample)
MX (1) MX356281B (enExample)
PL (1) PL2358361T3 (enExample)
PT (1) PT2358361T (enExample)
WO (1) WO2010057869A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101689688B1 (ko) * 2008-11-18 2016-12-26 유씨비 파마, 에스.에이. ２­옥소­１­피롤리딘 유도체를 포함하는 지연 방출형 제형
EP3397253A1 (en) 2015-12-30 2018-11-07 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of seizure-related disorders
US20190125725A1 (en) * 2016-05-12 2019-05-02 Jubilant Generics Limited Pharmaceutical compositions comprising brivaracetam
EP4337176B1 (en) * 2021-05-11 2025-07-16 Advicenne Prolonged-release pharmaceutical composition for oral administration of sultiame
CN117355296A (zh) * 2021-05-11 2024-01-05 阿德维斯尼公司 用于口服施用舒噻美的延长释放药物组合物
CN115721624A (zh) * 2021-08-25 2023-03-03 北京海美源医药科技有限公司 一种布立西坦药物组合物及其制备方法和其应用
TR2023017170A1 (tr) * 2023-12-13 2025-06-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Bri̇varasetam i̇çeren bi̇r saşe formülasyonu

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
AU2005325930B2 (en) 2005-01-27 2012-01-19 Alembic Limited Extended release formulation of Levetiracetam
US20070298098A1 (en) * 2005-02-16 2007-12-27 Elan Pharma International Limited Controlled Release Compositions Comprising Levetiracetam
WO2006088864A1 (en) * 2005-02-16 2006-08-24 Elan Pharma International Limited Controlled release compositions comprising levetiracetam
ES2403069T3 (es) * 2005-02-22 2013-05-13 Sun Pharma Advanced Research Company Ltd Composición oral de liberación controlada que contiene levetiracetam
CA2600282A1 (en) * 2005-03-29 2006-10-05 Roehm Gmbh Multiparticulate pharmaceutical form comprising pellets with a substance having a modular effect in relation to active ingredient release
FR2897267A1 (fr) * 2006-02-16 2007-08-17 Flamel Technologies Sa Formes pharmaceutiques multimicroparticulaires pour administration per os
EP2041084B1 (en) * 2006-06-08 2013-11-06 UCB Pharma, S.A. Co-crystals of pyrrolidinones
NZ575171A (en) * 2006-08-31 2012-04-27 Aptalis Pharmatech Inc Drug delivery systems comprising solid solutions of weakly basic drugs
WO2008062446A2 (en) * 2006-09-14 2008-05-29 Alembic Limited An extended release composition of levetiracetam, which exhibits no adverse food effect
CN101801356B (zh) * 2007-09-21 2016-10-19 赢创罗姆有限公司 耐受乙醇影响的非阿片类的pH依赖性受控释放的药物组合物
DK2273975T3 (da) 2008-03-03 2014-06-30 Ucb Pharma Sa Farmaceutiske opløsninger, fremgangsmåde til fremstilling og terapeutiske anvendelser

Also Published As

Publication number Publication date
ES2602606T3 (es) 2017-02-21
AU2009317279B2 (en) 2013-10-24
MX2011004572A (es) 2011-06-17
IL212271A0 (en) 2011-06-30
KR20110089184A (ko) 2011-08-04
JP5954889B2 (ja) 2016-07-20
EP2358361B1 (en) 2016-09-14
JP2015143256A (ja) 2015-08-06
WO2010057869A1 (en) 2010-05-27
CA2741038C (en) 2015-01-13
DK2358361T3 (en) 2016-12-12
EA019583B1 (ru) 2014-04-30
US20110274762A1 (en) 2011-11-10
CN104083341A (zh) 2014-10-08
PL2358361T3 (pl) 2017-02-28
CA2741038A1 (en) 2010-05-27
PT2358361T (pt) 2016-11-18
KR101788804B1 (ko) 2017-10-20
IL212271A (en) 2016-10-31
JP2012509356A (ja) 2012-04-19
HUE030963T2 (en) 2017-06-28
EP2358361A1 (en) 2011-08-24
CN102215828A (zh) 2011-10-12
EA201100753A1 (ru) 2012-01-30
US8460712B2 (en) 2013-06-11
KR20170007528A (ko) 2017-01-18
BRPI0921301A2 (pt) 2015-12-29
MX356281B (es) 2018-05-22
AU2009317279A1 (en) 2010-05-27

Similar Documents

Publication Publication Date Title
CN102215829B (zh) 含有2-氧代-1-吡咯烷衍生物的延长释放制剂
AU2010215646B2 (en) Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives
KR101257918B1 (ko) 콜린 알포세레이트 또는 이의 약학적으로 허용되는 염을 포함하는 서방형 약학 조성물 및 이의 제조방법
JP2015143256A (ja) ２−オキソ−１−ピロリジン誘導体を含む持続放出製剤
HK1159502A (en) Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivate
HK1159503B (en) Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivative
CA2635949A1 (en) Controlled release formulation of divalproic acid and its derivatives